High prevalence and underdiagnosis of osteoporosis in total hip arthroplasty candidates: a comprehensive assessment using bone mineral density, trabecular bone score, and bone turnover markers Authors: Shinichi Ueki, Takeshi Shoji, Takuma Yamasaki, Hiroyuki Morita, Yosuke Kozuma, Naoto Nakayama, Nobuo Adachi Published: 2025 ABSTRACT BackgroundTotal hip arthroplasty (THA) effectively alleviates symptoms in individuals with hip osteoarthritis. However, some candidates may have undiagnosed osteoporosis, and bone mineral density (BMD) alone may not sufficiently reflect bone fragility. The trabecular bone score (TBS) and bone turnover markers (BTMs) provide additional information on bone quality and metabolism. This study aimed to comprehensively evaluate osteoporosis prevalence using BMD, TBS, and BTMs, and to assess whether preoperative osteoporosis affects postoperative pain and patient-reported outcome measures (PROMs).MethodsThis retrospective study included 357 patients who underwent primary THA. Comprehensive evaluation involved dual-energy X-ray absorptiometry to assess BMD and lumbar TBS, along with serum levels of tartrate-resistant acid phosphatase 5b (TRACP-5b), and 25-hydroxyvitamin D (25(OH)D). The subsequent analysis excluded patients receiving preoperative osteoporosis treatment (n = 33) to avoid treatment-related confounding. Patients (n = 324) were initially stratified by sex, and then classified as normal, osteopenia, or osteoporosis group based on total hip BMD. Postoperative outcomes were assessed using the Numerical Rating Scale for pain and the Hip Disability and Osteoarthritis Outcome Score for Joint Replacement for PROMs at preoperatively and 12 months postoperatively.ResultsOsteoporosis and osteopenia were identified in 23.8% and 37.5% of all patients, respectively. TBS revealed compromised bone microarchitecture (Low TBS) in 25.7% of patients. Elevated TRACP-5b and vitamin D deficiency were observed in 15.6% and 72.3% of patients, respectively. Only 9.2% received osteoporosis pharmacologic treatment. No complications were observed within 12 months postoperatively. In only female patients, the osteopenia and osteoporosis groups, compared with the normal group, showed significantly lower TBS and 25(OH)D levels, and significantly higher TRACP-5b levels (p < 0.05); however, no significant differences were observed between the osteopenia and osteoporosis groups for these parameters. Furthermore, the improvement in HOOS JR scores from baseline to 12 months was significantly lower in the osteoporosis group compared with the normal and osteopenia groups (p = 0.02).ConclusionThis comprehensive assessment, which included BMD, TBS and BTMs, revealed that female patients exhibited abnormalities in bone microarchitecture and bone turnover starting from the osteopenia stage. Furthermore, the osteoporosis group showed a significantly lower improvement in PROMs 12 months postoperatively. Introduction Total hip arthroplasty (THA), often referred to as the operation of the century [1], is a widely performed procedure associated with high patient satisfaction, substantial pain relief, improved physical function, and enhanced quality of life (QOL) [2]. As the global population ages, the number of older adults undergoing THA has markedly increased [3, 4]. Concurrently, the prevalence of osteoporosis in this population has risen, contributing to an increase in peri-prosthetic fractures [5]. Although preventing osteoporosis-related complications is critical in patients undergoing THA, diagnosis and treatment remain suboptimal [6, 7]. Osteoporosis is a recognized risk factor for complications such as peri-prosthetic fractures and aseptic loosening [8, 9], both of which can adversely affect implant survival and patient’s QOL [10]. It is also associated with early implant migration, delayed osseointegration and an elevated risk of stress shielding and peri-prosthetic fractures following THA [8, 11–13]. Therefore, both bone quantity and quality are essential considerations for achieving durable implant fixation, underscoring the need for thorough preoperative bone health evaluation. Although some studies have reported osteoporosis prevalence using bone mineral density (BMD) among THA candidates [6, 7, 14], few have assessed trabecular bone score (TBS) and bone turnover markers (BTMs) in this context [6]. TBS offers a surrogate measure of trabecular microarchitecture [15, 16], while BTMs reflect bone remodeling activity, [17, 18], providing insights beyond BMD alone. Furthermore, the relationship between preoperative osteoporosis and postoperative persistent pain or patient-reported outcome measures (PROMs) remains unclear. This study aimed to comprehensively evaluate osteoporosis management among patients with hip osteoarthritis undergoing THA. Specifically, we sought to evaluate the prevalence of osteoporosis using BMD, TBS, and BTMs; assess pharmacologic treatment rates; and determine whether preoperative osteoporosis influences postoperative pain and PROMs. Material and methods This retrospective study adhered to the ethical principles of the Declaration of Helsinki and received approval from the Hiroshima University Hospital ethics committee. Written informed consent was obtained from all patients. Study population Between April 2021 and October 2023, 382 patients underwent primary THA for hip osteoarthritis (OA) at our institution. Radiographic grading confirmed all cases as Kellgren–Lawrence grade 3 or 4. Patients were excluded if they had prior hip surgery on the operative side, underwent contralateral THA during follow-up, or were lost to follow-up. A total of 357 patients (60 men, 297 women; mean age, 69.7 years) met the inclusion criteria. This study conducted a comprehensively evaluation of osteoporosis and investigate the relationships among BMD, TBS, and BTM, as well as to determine the prevalence of osteoporosis pharmacologic treatment. A retrospective chart review was conducted to identify preoperative pharmacologic treatment for osteoporosis. Treatments included bisphosphonates, teriparatide, denosumab, romosozumab, and selective estrogen receptor modulators (SERMs). Based on medication records at hospital admission, patients who had been prescribed any of these agents were classified as having received osteoporosis treatment. In a subsequent primary analysis, patients receiving osteoporosis medications were excluded to eliminate the potential influence of these agents on BMD, TBS, and BTM (Fig. 1). All THAs were performed by a single surgeon using the anterolateral supine approach. The all implants were cementless, with both the acetabular cup and femoral taper wedge stem secured through press-fit techniques. The acetabular cup was inserted with the assistance of the CT-based navigation system, and the femoral stem was inserted under fluoroscopy for correct alignment and positioning. Postoperative care was standardized, including pain management and rehabilitation.Fig.1Flowchart of the distribution of all participants in the study. THA, total hip arthroplasty; BMD, bone mineral density Flowchart of the distribution of all participants in the study. THA, total hip arthroplasty; BMD, bone mineral density Preoperative evaluation of osteoporosis BMD was assessed via dual-energy X-ray absorptiometry (DEXA) using the Horizon Wi system (HOLOGIC®, USA) within 1 month before surgery. Scans of the lumbar spine and the operative-side hip were performed per manufacturer guidelines. Osteoporosis was defined as a T-score ≤ − 2.5 and osteopenia as a T-score between − 1 and − 2.5, based on World Health Organization criteria [19]. TBS, derived from lumbar DEXA scans, was calculated using TBS iNsight software (Medimaps Group®, Switzerland). TBS provides an indirect index of trabecular microarchitecture and independently predicts spine and major osteoporotic fracture risk [20, 21]. The TBS values were determined for L1–L4, with a low TBS being defined as < 1.230, a threshold that has been suggested as indicative of compromised trabecular microarchitecture according to previous study [22]. Tartrate-resistant acid phosphatase 5b (TRACP-5b; reference range: male 170–590 mU/dL; female 250–760 mU/dL), total procollagen type 1 amino-terminal propeptide (P1NP; male 18.1–74.1 μg/L; female 26.4–98.2 μg/L), and 25-hydroxyvitamin D [25(OH)D] serum levels assessed using a chemiluminescent immunoassay (CLIA) were measured one month preoperatively. TRACP-5b and P1NP values deviating from the reference ranges described above were defined as “low” or “high”. Furthermore, in this study, elevated TRACP-5b levels were defined as “high bone turnover,” whereas decreased levels were defined as “low bone turnover”. Vitamin D was considered insufficient if < 30 ng/mL and deficient if < 20 ng/mL. Post-operative complication, persistent pain, and patient-reported outcome measures The incidence of postoperative complications, including infection, dislocation, and periprosthetic fracture, was retrospectively investigated from medical records at 12 months after surgery. Pain in the operated hip was assessed using the Numerical Rating Scale (NRS). PROMs were evaluated using the Hip Disability and Osteoarthritis Outcome Score for Joint Replacement (HOOS JR), scored from 0 to 100, with higher scores indicating better outcomes [23, 24]. All patients completed validated assessments both preoperatively and at 12 months postoperatively. Patients were initially stratified by sex, and then classified into three groups based on total hip BMD: osteoporosis (T-score ≤ − 2.5), osteopenia (T-score − 1 to − 2.5), and normal (T-score > − 1) (Fig. 1). Total hip BMD has been reported to provide better precision and to be less affected by localized degenerative changes, particularly in patients with hip osteoarthritis. Therefore, total hip BMD was used in this study as a more reliable index of proximal femoral bone strength [25]. Comparisons among groups included pre and postoperative NRS and HOOS JR scores, BTMs, lumbar TBS. Furthermore, the improvement in HOOS JR scores from preoperative to 12 months postoperatively was compared among the BMD groups. Data analysis Statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University), a graphical interface for R (The R Foundation for Statistical Computing, Vienna, Austria). Group comparisons were conducted using the chi-square test and the Kruskal–Wallis test with Steel–Dwass correction. Data are presented as mean (standard deviation), with statistical significance set at P < 0.05. In addition, within-group effect sizes for PROMs were calculated as standardized mean changes (Cohen’s d = mean change / SD of change). 95% confidence intervals (CI) for Cohen’s d were estimated using an approximate standard error (CI = d ± 1.96 × SE(d)). All tests were two-sided with α = 0.05. The minimal clinically important difference (MCID) for the HOOS Jr was defined as 23 points, according to previously published literature [26]. Results Based on a retrospective review of medical charts, no patients experienced adverse events such as hip dislocation (0%), infection (0%), or periprosthetic fracture (0%) within 12 months postoperatively. Among the 357 patients of comprehensive osteoporosis assessment group evaluated, 85 (23.8%) were diagnosed with osteoporosis and 134 (37.5%) with osteopenia based on DEXA of the lumbar spine or total hip. Figure 2 shows the histogram of lumbar spine and total hip BMD. Low TBS, indicating impaired bone microarchitecture, was observed in 92 patients (25.7%) (Fig. 3). Of these, 39 patients (42.4%) did not meet the diagnostic criteria for osteoporosis, suggesting subclinical deterioration of bone quality.Fig.2Histogram showing the distribution of lumbar spine and total hip T- scores. a T score of lumbar spine. b T score of total hip. Vertical lines indicate diagnostic thresholds for osteoporosis-related categories (T-score = − 1.0 and − 2.5), corresponding to osteopenia and osteoporosis, respectivelyFig.3Histogram showing the distribution of trabecular bone score. Vertical line indicates the diagnostic threshold for low TBS (TBS < 1.230), analogous to a T-score < − 2.5. BMD, bone mineral density; TBS, trabecular bone score Histogram showing the distribution of lumbar spine and total hip T- scores. a T score of lumbar spine. b T score of total hip. Vertical lines indicate diagnostic thresholds for osteoporosis-related categories (T-score = − 1.0 and − 2.5), corresponding to osteopenia and osteoporosis, respectively Histogram showing the distribution of trabecular bone score. Vertical line indicates the diagnostic threshold for low TBS (TBS < 1.230), analogous to a T-score < − 2.5. BMD, bone mineral density; TBS, trabecular bone score Serum levels of TRACP-5b, total P1NP, and 25(OH)D are presented in Fig. 4. The mean preoperative levels of BTMs were as follows: TRACP-5b; 472.2 (185.9) mU/dL, P1NP; 63.2 (22.2) μg/L, and 25(OH)D; 16.6 (6.4) ng/mL. Elevated TRACP-5b levels, reflecting high bone turnover, were found in 56 patients (15.6%), while low turnover was identified in 25 patients (7.0%). Vitamin D deficiency was widespread, affecting 258 patients (72.3%), while 88 patients (24.6%) had insufficient levels.Fig.4Serum Levels of Bone Turnover Markers (TRACP-5b and Total P1NP) and 25-hydroxyvitamin D. TRACP-5b (normal range: male 170–590 mU/dL; female 250–760 mU/dL) and P1NP (normal range: male 18.1–74.1 μg/L; female 26.4–98.2 μg/L) values deviating from the reference ranges were defined as “low” or “high”. 25 (OH) D was considered insufficient if < 30 ng/mL and deficient if < 20 ng/mL. TRACP-5b, Serum tartrate-resistant acid phosphatase 5b; Total P1NP, total procollagen type 1 amino-terminal propeptide; 25 (OH) D, 25-hydroxyvitamin D Serum Levels of Bone Turnover Markers (TRACP-5b and Total P1NP) and 25-hydroxyvitamin D. TRACP-5b (normal range: male 170–590 mU/dL; female 250–760 mU/dL) and P1NP (normal range: male 18.1–74.1 μg/L; female 26.4–98.2 μg/L) values deviating from the reference ranges were defined as “low” or “high”. 25 (OH) D was considered insufficient if < 30 ng/mL and deficient if < 20 ng/mL. TRACP-5b, Serum tartrate-resistant acid phosphatase 5b; Total P1NP, total procollagen type 1 amino-terminal propeptide; 25 (OH) D, 25-hydroxyvitamin D Only 33 patients (9.2%) were receiving pharmacologic osteoporosis treatment before THA. The distribution included 21 patients on bisphosphonates, one on teriparatide, two on denosumab, and nine on SERMs. Tables 1 and 2 presents a comparative analysis of demographic data, TBS, and BTMs, as well as pre- and postoperative pain scores and PROMs, among the primary analysis group defined by total hip BMD, stratified by sex after excluding patients who had received osteoporosis treatment. In male patients, there were no significant differences in any parameters between the osteopenia or osteoporosis groups and the normal group. In female patients, compared with the normal group, both the osteopenia and osteoporosis groups showed significantly lower TBS of the lumbar spine, total P1NP, and 25(OH)D levels, and significantly higher TRACP-5b levels. However, no significant differences in TBS or bone turnover markers were observed between the osteopenia and osteoporosis groups. Pre- and postoperative NRS and HOOS Jr scores did not differ significantly among the three groups. However, the mean change from baseline in HOOS Jr at 12 months was 47.5 ± 12.6 in the normal group, 47.1 ± 9.5 in osteopenia group, and 43.7 ± 15.6 in osteoporosis group, (p = 0.02). Within-group standardized mean changes (Cohen’s d) indicated large effect sizes: Normal d = 3.77 (95% CI, 3.20–4.34), Osteopenia d = 4.96 (95% CI, 4.31–5.61), and Osteoporosis d = 2.80 (95% CI, 2.20–3.40). Although all groups showed mean improvements exceeding the MCID for the HOOS Jr (23 points). The mean improvement in the osteoporosis group was approximately 4 points smaller than that in the normal and osteopenia groups. This difference was statistically significant but smaller than the MCID threshold, may not represent a clinically meaningful difference.Table 1Male: a comparative analysis of the groups based on total hip BMDNormalOsteopeniaOsteoporosispNumber (patients)4556Age (years)67.9 (9.3)68.4 (8.6)69.5 (6.0)0.99Body mass index (kg/ m2)25.4 (2.7)24.8 (4.4)24.5 (5.5)0.96TBS T score of lumbar spine− 0.5 (0.8)− 1.1 (0.8)− 1.0 (0.5)0.24Low TBS distribution (n (%))3 (6.6)1 (20.0%)0 (0.0%)0.36TRACP-5b (mU/dL)427.3 (148.6)490.6 (146.3)464.5 (173.9)0.61Total P1NP (μg/L)58.6 (18.8)61.3 (11.5)60.3 (8.8)0.6025-hydroxyvitamin D (ng/mL)19.4 (7.9)16.7 (3.9)18.9 (6.9)0.75Use of steroids (n (%))0 (0.0%)1 (20.0%)0 (0.0%)1.0Preoperative NRS8.9 (0.8)9.2 (0.6)8.8 (1.1)0.68Preoperative HOOS JR44.6 (20.1)42.6 (15.5)43.3 (14.6)0.53Postoperative NRS1.0 (1.1)0.8 (0.6)1.3 (1.1)0.63Postoperative HOOS JR88.8 (11.6)90.1 (11.7)86.6 (12.8)0.48Improvement of HOOS JR44.2 (21.7)48.1 (18.5)43.5 (12.3)0.68Data were presented as the mean (standard deviation)BMD, bone mineral density; TBS, trabecular bone score; TRACP-5b, Serum tartrate-resistant acid phosphatase 5b; Total P1NP, total procollagen type 1 amino-terminal propeptide; NRS, Numerical Rating Scale; HOOS JR, The Hip disability and Osteoarthritis Outcome Score, Joint Replacement*p < 0.05, **p < 0.01: Significantly different from the normal groupTable 2Female: a comparative analysis of the groups based on total hip BMDNormalOsteopeniaOsteoporosispNumber (patients)9512152Age (years)68.2 (9.6)70.3 (8.0)74.2 (7.8)**†< 0.01Body mass index (kg/ m2)25.3 (3.7)24.1 (3.5)22.7 (3.4)**†< 0.01TBS T score of lumbar spine− 1.1 (0.8)− 2.0 (1.0) **− 2.1 (0.7)**< 0.01Low TBS distribution (n (%))8 (8.4%)47 (38.8%) **28 (53.8%)**< 0.01TRACP-5b (mU/dL)441.1 (167.7)485.8 (203.5)*535.3.9 (194.1)*0.03Total P1NP (μg/L)72.3 (18.3)61.3 (24.6)*63.3 (25.2)*0.0225-hydroxyvitamin D (ng/mL)17.4 (6.5)15.1 (5.4)*14.4 (6.1)*0.02Use of steroids (n (%))1 (1.9%)5 (4.1%)4 (4.2%)*0.04Preoperative NRS8.9 (1.1)8.9 (1.4)8.5 (1.4)0.36Preoperative HOOS JR41.9 (13.3)42.2 (12.9)41.2 (13.6)0.88Postoperative NRS1.1 (1.1)1.1 (1.4)1.5 (1.5)0.27Postoperative HOOS JR89.7 (10.6)90.5 (12.7)84.4 (10.6)0.31Improvement of HOOS JR47.5 (12.6)47.1 (9.5)43.7 (15.6)*†0.02Data were presented as the mean (standard deviation)BMD, bone mineral density; TBS, trabecular bone score; TRACP-5b, Serum tartrate-resistant acid phosphatase 5b; Total P1NP, total procollagen type 1 amino-terminal propeptide; NRS, Numerical Rating Scale; HOOS JR, The Hip disability and Osteoarthritis Outcome Score, Joint Replacement*p < 0.05, **p < 0.01: Significantly different from the normal group†p < 0.05, ††p < 0.01: Significantly different between the osteoporosis and osteopenia groups Table 1Male: a comparative analysis of the groups based on total hip BMDNormalOsteopeniaOsteoporosispNumber (patients)4556Age (years)67.9 (9.3)68.4 (8.6)69.5 (6.0)0.99Body mass index (kg/ m2)25.4 (2.7)24.8 (4.4)24.5 (5.5)0.96TBS T score of lumbar spine− 0.5 (0.8)− 1.1 (0.8)− 1.0 (0.5)0.24Low TBS distribution (n (%))3 (6.6)1 (20.0%)0 (0.0%)0.36TRACP-5b (mU/dL)427.3 (148.6)490.6 (146.3)464.5 (173.9)0.61Total P1NP (μg/L)58.6 (18.8)61.3 (11.5)60.3 (8.8)0.6025-hydroxyvitamin D (ng/mL)19.4 (7.9)16.7 (3.9)18.9 (6.9)0.75Use of steroids (n (%))0 (0.0%)1 (20.0%)0 (0.0%)1.0Preoperative NRS8.9 (0.8)9.2 (0.6)8.8 (1.1)0.68Preoperative HOOS JR44.6 (20.1)42.6 (15.5)43.3 (14.6)0.53Postoperative NRS1.0 (1.1)0.8 (0.6)1.3 (1.1)0.63Postoperative HOOS JR88.8 (11.6)90.1 (11.7)86.6 (12.8)0.48Improvement of HOOS JR44.2 (21.7)48.1 (18.5)43.5 (12.3)0.68Data were presented as the mean (standard deviation)BMD, bone mineral density; TBS, trabecular bone score; TRACP-5b, Serum tartrate-resistant acid phosphatase 5b; Total P1NP, total procollagen type 1 amino-terminal propeptide; NRS, Numerical Rating Scale; HOOS JR, The Hip disability and Osteoarthritis Outcome Score, Joint Replacement*p < 0.05, **p < 0.01: Significantly different from the normal group Male: a comparative analysis of the groups based on total hip BMD Data were presented as the mean (standard deviation) BMD, bone mineral density; TBS, trabecular bone score; TRACP-5b, Serum tartrate-resistant acid phosphatase 5b; Total P1NP, total procollagen type 1 amino-terminal propeptide; NRS, Numerical Rating Scale; HOOS JR, The Hip disability and Osteoarthritis Outcome Score, Joint Replacement *p < 0.05, **p < 0.01: Significantly different from the normal group Table 2Female: a comparative analysis of the groups based on total hip BMDNormalOsteopeniaOsteoporosispNumber (patients)9512152Age (years)68.2 (9.6)70.3 (8.0)74.2 (7.8)**†< 0.01Body mass index (kg/ m2)25.3 (3.7)24.1 (3.5)22.7 (3.4)**†< 0.01TBS T score of lumbar spine− 1.1 (0.8)− 2.0 (1.0) **− 2.1 (0.7)**< 0.01Low TBS distribution (n (%))8 (8.4%)47 (38.8%) **28 (53.8%)**< 0.01TRACP-5b (mU/dL)441.1 (167.7)485.8 (203.5)*535.3.9 (194.1)*0.03Total P1NP (μg/L)72.3 (18.3)61.3 (24.6)*63.3 (25.2)*0.0225-hydroxyvitamin D (ng/mL)17.4 (6.5)15.1 (5.4)*14.4 (6.1)*0.02Use of steroids (n (%))1 (1.9%)5 (4.1%)4 (4.2%)*0.04Preoperative NRS8.9 (1.1)8.9 (1.4)8.5 (1.4)0.36Preoperative HOOS JR41.9 (13.3)42.2 (12.9)41.2 (13.6)0.88Postoperative NRS1.1 (1.1)1.1 (1.4)1.5 (1.5)0.27Postoperative HOOS JR89.7 (10.6)90.5 (12.7)84.4 (10.6)0.31Improvement of HOOS JR47.5 (12.6)47.1 (9.5)43.7 (15.6)*†0.02Data were presented as the mean (standard deviation)BMD, bone mineral density; TBS, trabecular bone score; TRACP-5b, Serum tartrate-resistant acid phosphatase 5b; Total P1NP, total procollagen type 1 amino-terminal propeptide; NRS, Numerical Rating Scale; HOOS JR, The Hip disability and Osteoarthritis Outcome Score, Joint Replacement*p < 0.05, **p < 0.01: Significantly different from the normal group†p < 0.05, ††p < 0.01: Significantly different between the osteoporosis and osteopenia groups Female: a comparative analysis of the groups based on total hip BMD Data were presented as the mean (standard deviation) BMD, bone mineral density; TBS, trabecular bone score; TRACP-5b, Serum tartrate-resistant acid phosphatase 5b; Total P1NP, total procollagen type 1 amino-terminal propeptide; NRS, Numerical Rating Scale; HOOS JR, The Hip disability and Osteoarthritis Outcome Score, Joint Replacement *p < 0.05, **p < 0.01: Significantly different from the normal group †p < 0.05, ††p < 0.01: Significantly different between the osteoporosis and osteopenia groups Discussion This study comprehensively assessed osteoporosis prevalence in patients with hip osteoarthritis who underwent THA, using BMD, TBS, and BTMs. Additionally, it examined the influence of preoperative osteoporosis on postoperative persistent pain and PROMs. The results demonstrated a high prevalence of osteoporosis (23.8%) and osteopenia (37.5%). Nonetheless, only 9.2% of patients received pharmacological osteoporosis treatment prior to surgery. A low TBS was observed in 25.7% of patients, and 42.4% of these did not meet the DEXA-based diagnostic criteria for osteoporosis, indicating impaired bone microarchitecture despite normal BMD. High and low bone turnover were identified in 10.1% and 7.0% of patients, respectively. Vitamin D deficiency was common, affecting 72.3% of the cohort. In the subgroup analysis stratified by sex and total hip BMD, no significant differences in TBS or BTMs were observed among male patients. However, in female patients, both the osteopenia and osteoporosis groups showed significantly lower TBS, higher TRACP-5b levels, and lower P1NP and 25(OH)D levels compared with the normal group. Notably, in female patients, the improvement rate in HOOS Jr scores from preoperative to 12 months postoperatively was significantly lower in the osteoporosis group compared with the normal and osteopenia groups. Previous research has identified a tendency for osteoporosis to be underdiagnosed and undertreated in patients undergoing THA, with assessments frequently relying solely on BMD [7, 14]. However, BMD does not fully capture bone quality or strength, especially in older adults or those with osteoarthritis, where degenerative changes may overestimate BMD readings, particularly in the spine [27, 28]. By incorporating TBS and BTMs, our study provided a broader assessment of bone health. The prevalence of osteoporosis and osteopenia was consistent with previous studies, which reflect the aging profile and increased fragility of THA candidates [6, 7, 14]. Importantly, TBS revealed compromised bone microarchitecture in patients without osteoporosis by BMD criteria. The significantly lower TBS observed in females with osteopenia in this study suggests that deterioration of bone microarchitecture and bone quality may already occur before reaching the diagnostic threshold for osteoporosis defined by BMD. Prior studies on osteoporotic fractures also reported that many postmenopausal females with hip fractures had BMD values above the osteoporosis threshold [29, 30], highlighting the relevance of microarchitectural assessment. Existing literature supports the utility of lumbar spine TBS in predicting major osteoporotic, vertebral, and hip fractures in postmenopausal females and in males aged ≥ 50 years [15]. The findings further highlight the underutilization of pharmacological osteoporosis treatment, with only 9.2% of patients receiving therapy before surgery. This low rate may stem from underdiagnosis or limited awareness of the importance of osteoporosis management in patients undergoing THA, despite its relevance to implant longevity, risk of periprosthetic fractures, and overall outcomes [10, 11]. Notably, 96% of orthopedic surgeons reportedly do not measure BMD before joint arthroplasty [31]. The International Society of Clinical Densitometry (ISCD) recommends pre-operative BMD assessment for men over 70 years and women over 65 years, and this study also suggests the need for osteoporosis treatment interventions in the context of joint arthroplasty [25]. Furthermore, it has been reported that perioperative treatment of osteoporosis in total hip arthroplasty reduced postoperative peri-prosthetic fractures and stress shielding [32, 33]. TRACP-5b analysis revealed high bone turnover in 15.6% and low turnover in 7.0% of patients prior to surgery. In the sex-stratified analysis, female patients, not only in the osteoporosis group but also in the osteopenia group, exhibited higher TRACP-5b levels and lower P1NP and 25(OH)D levels compared with the normal group, indicating an imbalance in bone turnover characterized by increased resorption and reduced formation. Elevated TRACP-5b has been associated with late aseptic loosening in THA due to activity of resorbing multinucleated cells [34]. Therefore, elevated preoperative TRACP-5b levels may indicate increased bone resorption activity, which could be associated with a higher risk of complications such as aseptic loosening. Conversely, low bone turnover has been linked to impaired osseointegration of titanium implants [35], increasing the risk of early stem subsidence and periprosthetic fractures [8]. Early identification of these patients and the use of osteogenesis-promoting agents may reduce complication rates. Vitamin D deficiency, present in nearly 75% of patients, is consistent with findings in older or chronically ill populations [36]. Despite its known role in bone metabolism, muscle strength, fall risk, and postoperative recovery, it remains frequently overlooked in preoperative assessments [37]. These findings support routine screening for metabolic bone disorders in patients undergoing THA. Therefore, a comprehensive preoperative assessment including TBS and BTMs may help optimize the evaluation of bone microarchitecture and bone quality, and identify osteopenia patients who could benefit from early pharmacologic intervention to reduce postoperative complications. In addition, beyond the BTMs utilized in this study, other biomarkers and gene-based predictive tests for assessing treatment response and predicting complications are currently under investigation. Continued advancements in BTMs are also anticipated [38–43]. Although osteoporosis is recognized as a risk factor for postoperative complications such as periprosthetic fracture, dislocation, and infection, no such complications occurred in this cohort. While the observed differences between groups did not exceed the MCID threshold and thus may not be clinically significant, patients with osteoporosis exhibited notably less improvement in PROMs at 12 months postoperatively. Previous studies have reported that the presence of osteoporosis was associated with 1.4-fold higher odds of not achieving clinically meaningful improvement in PROMs based on the Patient Acceptable Symptom State (PASS) and a 1.5-fold higher risk of dissatisfaction after surgery [44] However, other studies also have shown no significant association between osteoporosis and PROMs [45]. These discrepancies may be attributed to heterogeneous study populations, including the mixture of total hip and total knee arthroplasty cases, as well as inconsistent implant fixation methods (cemented vs. cementless). Future studies with standardized surgical techniques and fixation methods are warranted to clarify the independent impact of osteoporosis on postoperative outcomes. In this study, all patients underwent THA using cementless stems. Because osteoporosis has been shown to impair the initial fixation and increase micromotion of cementless stems [8], this impaired osseointegration may have contributed to the lower postoperative PROMs observed in osteoporotic patients. Furthermore, THA has been associated with a 25% increased fracture risk between 2.5 and 5 years postoperatively [46], suggesting that longer-term PROMs may reveal more significant different results. In addition, vertebral fractures can lead to increased pain and reduced activities of daily living [47, 48], and vertebral fractures following THA can also lead to posterior pelvic tilt, increasing the risk of anterior dislocation [49]. Therefore, THA should be viewed as an opportunity for early intervention with osteoporosis treatment to reduce long-term complications and potentially extend healthy life expectancy. In this study, women in the osteoporosis group had significantly lower BMI and a higher rate of corticosteroid use. Given the demonstrated efficacy of osteoporosis medications in patients with low BMI and glucocorticoid-induced osteoporosis [50, 51], early therapeutic intervention may be particularly necessary in this population. Furthermore, osteoporosis medications have been reported not only to increase bone mineral density and prevent fractures but also to reduce pain and improve clinical scores in osteoporotic patients[52–54], indicating that future studies should investigate their potential effects on postoperative PROMs. This study’s strength lies in its comprehensive assessment of bone health in patients undergoing THA, incorporating BMD, TBS, and BTMs to evaluate osteoporosis prevalence and clinical relevance. By exposing the limitations of relying solely on BMD and emphasizing the underuse of pharmacologic treatment, the findings offer practical insights that may enhance preoperative screening and management strategies. However, this study has several limitations. First, the retrospective design may introduce selection bias and limit causal interpretation. Second, the use of a single-center and single-surgeon methodology may limit the generalizability of the findings. Although this approach minimizes variability associated with surgical planning and technique, which could affect postoperative PROMs, the potential for selection bias cannot be entirely dismissed. Third, only lumbar TBS was measured in this study, which may be affected by lumbar degenerative changes in elderly patients. However, the analysis was limited to the lumbar site because software for hip TBS measurement was not available at our institution. Although a method to evaluate hip bone microarchitecture (TBS hip) has been proposed [16], it remains underutilized. Future studies should explore the potential of hip TBS, which may provide additional information on proximal femoral bone quality. Fourth, the follow-up period of 12 months was relatively short and may not fully capture the long-term influence of osteoporosis on implant survival or other late complications. Fifth, this study did not include radiographic evaluations such as stem subsidence, stress shielding, or other imaging parameters of implant fixation. These radiographic outcomes are clinically important and may be influenced by bone quality; therefore, future studies should incorporate both radiological and clinical assessments to clarify the relationship between osteoporosis and implant performance. Conclusion This study highlights the significant prevalence of osteoporosis and diminished bone quality among individuals undergoing total hip arthroplasty, as well as the frequent underdiagnosis and insufficient treatment of osteoporosis within this cohort. In female patients, the postoperative enhancement in PROMs at 12 months was notably lower in those with osteoporosis, with abnormalities in TBS and BTM already apparent at the osteopenia stage. These findings indicate that a thorough preoperative assessment of bone health utilizing TBS and BTMs is crucial, and that early pharmacological intervention for osteoporosis should be considered not only for patients with confirmed osteoporosis but also for those with osteopenia undergoing THA.